---
title: "LAEKNA's annual loss narrowed to 229 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279617694.md"
description: "LAEKNA-B announced its 2025 annual performance, with revenue recorded at 107 million RMB (same below). Losses narrowed from 254 million RMB in the previous year to 229 million RMB, with a loss per share of 0.59 RMB. No dividend is declared"
datetime: "2026-03-18T14:00:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279617694.md)
  - [en](https://longbridge.com/en/news/279617694.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279617694.md)
---

# LAEKNA's annual loss narrowed to 229 million yuan

LAEKNA-B (02105.HK) announced its performance for the fiscal year 2025, with revenue recorded at RMB 107 million. The loss narrowed from RMB 254 million in the previous year to RMB 229 million, with a loss per share of 59 cents. No dividend is declared

### Related Stocks

- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)

## Related News & Research

- [CICC Sticks to Their Buy Rating for Laekna, Inc. (2105)](https://longbridge.com/en/news/283298518.md)
- [Bank of America Securities Reaffirms Their Buy Rating on Laekna, Inc. (2105)](https://longbridge.com/en/news/285640720.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)